- 1D
- 3D
- 1W
- 1M
- 6M
- 1Y
- 3Y
- 5Y
Announcements
- Notice of Results
- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
- Total Voting Rights and Block Listing Return
- Signing of Strategic Platform License
- MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
- Exercise of options and PDMR dealing
- Grant of Options, RSUs and PSUs and PDMR Dealing
- Filing of form 10-K for FY ended December 31, 2023
- Reports Q4 & FY 2023 Financial Results
- MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
More ▼
Key statistics
On Friday, MaxCyte Inc (MXCT:LSE) closed at 313.00, -28.05% below its 52-week high of 435.00, set on Apr 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 313.00 |
---|---|
High | 310.00 |
Low | 310.00 |
Bid | 296.00 |
Offer | 316.00 |
Previous close | 313.00 |
Average volume | 29.78k |
---|---|
Shares outstanding | 104.40m |
Free float | 98.17m |
P/E (TTM) | -- |
Market cap | 405.05m USD |
EPS (TTM) | -0.3675 USD |
Data delayed at least 20 minutes, as of Apr 19 2024 12:32 BST.
More ▼